Tricida (TCDAQ) Versus Its Competitors Head to Head Comparison
Tricida (TCDAQ) Versus Its Competitors Head to Head Comparison
Tricida (NASDAQ:TCDAQ – Get Rating) is one of 986 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it weigh in compared to its competitors? We will compare Tricida to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, profitability and dividends.
Tricida（NASDAQ：TCDAQ — 獲取評級）是「製藥製劑」行業 986 家上市公司之一，但與競爭對手相比，它的重量如何？我們將根據 Tricida 的估值、機構所有權、分析師建議、風險、盈利能力和股息等實力，將 Tricida 與相關業務進行比較。
Profitability
盈利
This table compares Tricida and its competitors' net margins, return on equity and return on assets.
此表格比較 Tricida 及其競爭對手的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Tricida | N/A | N/A | -103.81% |
| Tricida Competitors | -3,401.47% | -345.78% | -38.40% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 三重 | N/A | N/A | -103.81% |
| 第一競爭對手 | -3,401.47% | -345.78% | -38.40% |
Risk & Volatility
風險及波動性
Tricida has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Tricida's competitors have a beta of 0.93, indicating that their average stock price is 7% less volatile than the S&P 500.
Tricida 的測試版為 0.12，表明其股票價格的波動性比標普 500 低 88%。相比之下，Tricida 的競爭對手的測試版為 0.93，這表明他們的平均股價比標普 500 低了 7％ 的波動性。
Insider and Institutional Ownership
內幕和機構所有權
40.6% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 35.6% of Tricida shares are owned by company insiders. Comparatively, 15.6% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
所有「製藥製劑」公司的 40.6％ 股份由機構投資者擁有。Tricida 的 35.6％ 的股份由公司內部人員擁有。相比之下，所有「製藥製劑」公司的 15.6% 股份均由公司內部人士擁有。強大的機構擁有權表明，大型資金經理，捐贈基金和對沖基金認為公司有望實現長期增長。
Valuation and Earnings
估值及收益
This table compares Tricida and its competitors gross revenue, earnings per share (EPS) and valuation.
此表格比較 Tricida 及其競爭對手的總收入、每股盈利 (EPS) 和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Tricida | N/A | -$176.57 million | 0.00 |
| Tricida Competitors | $8.39 billion | $241.80 million | -3.67 |
| 總收入 | 淨收入 | 市盈比率 | |
| 三重 | N/A | -一億七千六百五十七萬美元 | 0.00 |
| 第一競爭對手 | 八百三十九億美元 | 二億四千一百八十萬 | -3.67 |
Tricida's competitors have higher revenue and earnings than Tricida. Tricida is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Tricida 的競爭對手擁有比 Tricida 更高的收益和收益。Tricida 的交易價格與收益比率高於競爭對手，這表明它目前比其他行業中的公司更昂貴。
Analyst Recommendations
分析師推薦
This is a breakdown of current ratings and recommmendations for Tricida and its competitors, as reported by MarketBeat.
這是 Tricida 及其競爭對手的當前評級和建議的細分，如 MarketBeat 報告的那樣。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tricida | 0 | 0 | 0 | 0 | N/A |
| Tricida Competitors | 4157 | 15005 | 41469 | 711 | 2.63 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 三重 | 0 | 0 | 0 | 0 | N/A |
| 第一競爭對手 | 4157 | 15005 | 41469 | 711 | 2.63 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 118.01%. Given Tricida's competitors higher possible upside, analysts clearly believe Tricida has less favorable growth aspects than its competitors.
作為一個集團，「製藥」公司的潛在上升空間為 118.01％。鑑於 Tricida 的競爭對手可能具有較高的上漲空間，分析師清楚地認為 Tricida 的增長方面比競爭對手不那麼有利。
Summary
摘要
Tricida competitors beat Tricida on 6 of the 10 factors compared.
Tricida 的競爭對手在 6 個因素中擊敗了 Tricida 的 10 個因素相比。
Tricida Company Profile
三公司簡介
(Get Rating)
(取得評分)
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.
天合股份有限公司是一家製藥公司。它專注於其產品 TRC101 的開發和商業化，這是一種非吸收，口服給藥的聚合物藥物，旨在治療慢性腎臟疾病患者的代謝性酸中毒。該公司由格里特·克拉納和克雷格·喬恩·霍克於 2013 年 5 月 22 日成立，總部位於加利福尼亞州南舊金山。
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.
接收「三日報」的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Tricida 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。